PHILADELPHIA, PA / ACCESS Newswire / January 28, 2026 / Kaskela Law LLC announces that it is investigating potential legal claims on behalf of long-term holders of ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI") common stock.
Click here to submit your information to the firm and to receive additional information about your legal rights and options: https://kaskelalaw.com/case/aspi/
Recently a federal securities fraud complaint was filed against ASPI on behalf of certain investors who purchased shares of the company’s stock between September 26, 2024 and November 26, 2024 (the "Relevant Period"). According to the complaint, during the Relevant Period, ASPI and certain senior executive officers issued a series of materially false and misleading statements to investors concerning the company’s business, operations and prospects.
Further according to the complaint, in October 2024, ASPI published press releases misleadingly promoting the commissioning of its first "quantum enrichment" plant to enrich Ytterbium, and its entry into a term sheet to build a plant to produce High Assay Low Enriched Uranium ("HALEU") and supply HALEU to a U.S.-based customer for a 10-year period. These announcements caused a dramatic surge in ASPI’s stock price, which the defendants promptly capitalized on by selling $18.6 million worth of ASPI stock to the public at an artificially inflated price.
As further detailed in the complaint, on November 26, 2024, Fuzzy Panda Research published a report based on research including interviews with nuclear energy industry executives and consultations with an applied physicist, which revealed significant problems facing ASPI’s claimed uranium enrichment technology, causing a 23.5% decline in ASPI’s stock price that day.
Then, on November 27, 2024, ASPI’s co-founder and CEO participated in an interview with a Canaccord Genuity stock analyst, in an attempt to rebut the claims made in the Fuzzy Panda Research report. However, in the course of the interview Mann revealed, to the analyst’s evident surprise, that ASPI had never enriched uranium or tested its technology on uranium, not even on a laboratory scale. On this news, ASPI’s share price fell an additional 14.2% on November 27, 2024.
In light of the foregoing, Kaskela Law is investigating whether ASPI’s officers and directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.
Current ASPI shareholders who have continuously held ASPI shares since at least prior to September 26, 2024 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) to receive additional information about this investigation and their legal rights and options at (484) 229 – 0750, via email at abell@kaskelalaw.com, or by clicking on the following link (or if necessary, by copying and pasting the link into your browser):
https://kaskelalaw.com/case/aspi/
Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis, and has assisted investors in recovering over $500 million. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.
CONTACT:
KASKELA LAW LLC
D. Seamus Kaskela, Esq.â?¯
Adrienne Bell, Esq.â?¯
18 Campus Blvd., Suite 100â?¯
Newtown Square, PA 19073â?¯
(484) 229 – 0750â?¯
www.kaskelalaw.com
This notice may constitute attorney advertising in certain jurisdictions.���
SOURCE: Kaskela Law LLC
View the original press release on ACCESS Newswire
COMTEX_472506159/2457/2026-01-28T07:59:34